Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
Soligenix Corporate Presentation
May 4, 2023
HyBryte Investor Sheet
Dr. Brian Poligone, Clinical Investigator for CTCL Phase 3 FLASH Study, Answers Questions About Patient Care and Treatment Options
29 Emmons Drive
Suite B-10 Princeton, NJ 08540
Subscribe For Alerts
If you would like to receive our Investor Relations updates, please sign up for email alerts.